openPR Logo
Press release

Shigella Vaccines Market – Higher Growth Rate & Forecast 2018 – 2026: MSD Wellcome Trust Hilleman Laboratories, Novartis (Novartis Vaccines Institute for Global Health), and GlaxoSmithKline plc

05-30-2019 09:04 AM CET | Business, Economy, Finances, Banking & Insurance

Press release from: Coherent Market Insights

Shigella Vaccines Market

Shigella Vaccines Market

Shigella is a gram-negative pathogenic enterobacteria that causes severe diarrhea and dysentery in humans. Symptoms associated with Shigella infection includes fever, stomach pain, tenesmus, watery diarrhea, vomiting, dehydration, and convulsions. Various strains of Shigella are encompassed, such as S. Dysenteriae, S. flexneri, S. sonnei and S. boydii. Each species of Shigella has different serotypes classified on the basis of the structure of O-antigens repeats that are the polysaccharides moiety of the lipopolysaccharide, a virulence factor consist of toxic lipid. According to the Centers for Disease Control and Prevention (CDC), in 2013, the average annual incidence of shigellosis in the U.S. was around 5 cases per 100,000 individuals. Bacillary dysentery with brutal epidemics are caused by S. dysenteriae by the production of shiga toxins whereas, the endemic form of disease is caused by the S. flexneri and S. sonnei. The bacillary dysentery is accompanied with fever, rectal inflammation, and abdominal cramps.

According to World Health Organization (WHO), nearly one million people die from Shigella infection annually. Moreover, the high incidence rate is seen among children less than five years age, travelers, and military personnel from industrialized economies. Shigella species have been identified from centuries and it represents a major threat to public health, due to non-availability of licensed vaccine and thus affecting overall Shigella vaccines market.

Download The PDF Brochure of This Business Report: https://www.coherentmarketinsights.com/insight/request-pdf/1110

Developing vaccine against Shigella infections is difficult, due to the diversity of Shigella species and their serotypes. Shigella genome is continuously modified by deletion and acquisition of genes mediated by the mobile genetic elements, such as plasmids, insertion sequences, and integrons. These modifications are the major foundation for the generation of novel antibiotic resistant strains and it also leads to the formation of novel Shigella serotype variants. Centers for Disease Control and Prevention (CDC) in April 2017, warned the physicians and public health officials in the U.S. by stating that the recent strains of Shigella bacteria shows the reduced susceptibility to ciprofloxacin, which is one of the main antibiotics recommended by WHO for the treatment of shigellosis.

Geographically, S. flexneri is the most frequent species occurred worldwide accounting for most cases in emerging economies. Whereas, the S. sonnei is prevalent in Brazil, China, Vietnam, and Bangladesh, due to rapid industrialization of these economies. The primary prevention of Shigella is based on the universal provision of portable sanitation and water methods along with personal and food hygiene. However, a low cost and effective vaccine would accelerate disease reduction across the globe.

Prokarium and Probiomed in January 2017, collaborated to manufacture orally-administrated vaccine to prevent diarrhea. The new vaccine is expected to be manufactured as a part of two-year collaboration having thermostable capabilities for a longer period. The new vaccine is expected to be delivered to the people living in the remote areas. Thermostable vaccine, which is manufactured approximately one third of the price of the conventional injectable vaccines helps to facilities the growth of Shigella vaccines market.

The new research trial drives the Shigella vaccines market
The University Of Maryland School Of Medicine (UM SOM) in August 2017 received US$ 2.47 Million grant from the National Institute of Allergy and Infectious Diseases (NIAID) to develop vaccine against Shigella and Enterotoxigenic Escherichia coli (ETEC) for the treatment of diarrheal disease. The researchers in the UM SOM’s Center for Vaccine Development (CVD) have developed Shigella-ETEC prototype vaccine, which has been tested in animals successfully. Moreover, the latest funding helps to translate prototype to a human vaccine for Phase 1 clinical trials.
The key players present in the global shigella vaccines market include MSD Wellcome Trust Hilleman Laboratories Pvt. Ltd., Novartis (Novartis Vaccines Institute for Global Health), and GlaxoSmithKline plc.

Request For Customization of This Business Report: https://www.coherentmarketinsights.com/insight/request-customization/1110

About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:
Mr.Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Shigella Vaccines Market – Higher Growth Rate & Forecast 2018 – 2026: MSD Wellcome Trust Hilleman Laboratories, Novartis (Novartis Vaccines Institute for Global Health), and GlaxoSmithKline plc here

News-ID: 1758803 • Views: 559

More Releases from Coherent Market Insights

U.S. Men’s Underwear Market Players Focus on Executing Business Expansion till …
Men's underwear is typically referred to as intimate clothing because it is worn next to the skin. They are mostly used to keep other clothing from becoming dirty due to sweat and to shape the body. Rayon, cotton, nylon, polyester, silk, and cotton are used to make these garments. They keep the private area dry and prevent damp stains while maintaining comfort. Furthermore, men's underwear supports the intimate shapes that
4.0% CAGR Expected In Global Cosmetic ingredients Market Size 2021 | BASF SE, Ak …
Cosmetic ingredients are substances used in the production of cosmetics such as creams, fragrances, moisturisers, and other similar items. Thickeners, moisturisers, preservatives, scents, water, and colours are all common constituents in cosmetics. Skin care, hair care, make-up, fragrance, oral care, and cosmetic goods all use cosmetic ingredients, which are divided into two categories: synthetic and natural ingredients. The global cosmetic ingredients market was valued at US$ 17,374.2 Mn in 2019 and
At a CAGR of 3.2%, White spirit Market Growth and Demand 2027 | ExxonMobil Corpo …
Mineral spirits, varsol, and petroleum spirits are all terms for white spirits, which are made from petroleum. Paints, aerosols, varnishes, asphalt products, lacquers, wood preservatives, and cleaning and degreasing machine parts all use it as an organic solvent. Varnishes, paints, and lacquers account for 60 percent of total white spirits usage in Europe. In the paint industry, it is mostly utilised as a solvent. Furthermore, in domestic applications, white spirits
Potato Chips Market industry rides on high demand, looking at expansions 2021 | …
Potato Chips market reports provides a comprehensive overview of the global market size and share. Potato Chips market data reports also provide a 5 year pre-historic and forecast for the sector and include data on socio-economic data of global. Key stakeholders can consider statistics, tables & figures mentioned in this report for strategic planning which lead to success of the organization. Get Sample Copy of This Report @ https://www.coherentmarketinsights.com/insight/request-sample/3109 Major

All 5 Releases


More Releases for Shigella

Shigella Vaccines Market 2020 To See Worldwide Massive Growth | Outlook, Trends, …
Coherent Market Insights added the most up-to-date research on “Shigella Vaccines Market” to its huge collection of research reports. The research analysis is a superb account of macroeconomic and microeconomic factors influencing the growth of the global Shigella Vaccines Market. This will help market players to make suitable changes in their approach towards attaining growth and maintaining their position in the industry. The global Shigella Vaccines Market is segmented as
Shigella Infection (Shigellosis) Therapeutics- Pipeline Analysis 2018
Shigella infection, also known as shigellosis, is a bacterial infection caused by a family of bacteria known as shigella. The main symptom of this infection is diarrhea, and can be passed through direct contact with the bacteria in the stool. Download the sample report @ https://www.pharmaproff.com/request-sample/1072 The other sign and symptoms associated with shigella infection are abdominal pain, cramps, and fever. Children between the age of two and four years are
Shigella Vaccines Market Explored in Latest Research to 2026 By Global Players N …
Shigella is a gram-negative pathogenic enterobacteria that causes severe diarrhea and dysentery in humans. Symptoms associated with Shigella infection includes fever, stomach pain, tenesmus, watery diarrhea, vomiting, dehydration, and convulsions. Various strains of Shigella are encompassed, such as S. dysenteriae, S. flexneri, S. sonnei and S. boydii. Each species of Shigella has different serotypes classified on the basis of the structure of O-antigens repeats that are the polysaccharides moiety of
The New Research Trial Drives The Shigella Vaccines Market
Shigella is a gram-negative pathogenic enterobacteria that causes severe diarrhea and dysentery in humans. Symptoms associated with Shigella infection includes fever, stomach pain, tenesmus, watery diarrhea, vomiting, dehydration, and convulsions. Various strains of Shigella are encompassed, such as S. dysenteriae, S. flexneri, S. sonnei and S. boydii. Each species of Shigella has different serotypes classified on the basis of the structure of O-antigens repeats that are the polysaccharides moiety of the lipopolysaccharide, a virulence
Shigella Infections - Pipeline Analysis with Ongoing Trends in Therapeutic Devel …
Market Research Hubs’ Shigella Infections-Pipeline Insights, 2017, report provides comprehensive insights of the ongoing therapeutic research and development across Shigella Infections. The report provides a complete understanding of the pipeline activities covering all clinical, pre-clinical and discovery stage products. A comparative pipeline therapeutics assessment of Shigella Infections by development stage, therapy type, route of administration and molecule type is also covered in the report. It also has a special feature
Research Report: Global Shigella Infections (Shigellosis) Market
MarketResearchReports.Biz presents this most up-to-date research on "Shigella Infections (Shigellosis)-API Insights, 2017" The active pharmaceutical ingredients worldwide market is in continuous development from the recent years. There is expected to be a major impact on the global API industry, with the large number of blockbuster drugs going off patent in the coming years. It is going to affect the revenue of the API market as generic drugs occupy the market. View Complete